Nitazoxanide Analogs Require Nitroreduction for Antimicrobial Activity in Mycobacterium smegmatis.

In this study, we aimed to decipher the natural resistance mechanisms of mycobacteria against novel compounds isolated by whole-cell-based high-throughput screening (HTS). We identified active compounds using Mycobacterium aurum. Further analyses were performed to determine the resistance mechanism of M. smegmatis against one hit, 3-bromo-N-(5-nitrothiazol-2-yl)-4-propoxybenzamide (3), which turned out to be an analog of the drug nitazoxanide (1). We found that the repression of the gene nfnB coding for the nitroreductase NfnB was responsible for the natural resistance of M. smegmatis against 3. The overexpression of nfnB resulted in sensitivity of M. smegmatis to 3. This compound must be metabolized into hydroxylamine intermediate for exhibiting antibacterial activity. Thus, we describe, for the first time, the activity of a mycobacterial nitroreductase against 1 analogs, highlighting the differences in the metabolism of nitro compounds among mycobacterial species and emphasizing the potential of nitro drugs as antibacterials in various bacterial species.

[1]  S. Cole.  Inhibiting Mycobacterium tuberculosis within and without , 2016, Philosophical Transactions of the Royal Society B: Biological Sciences.

[2]  K. Skolnik,et al.  Nontuberculous Mycobacteria in Cystic Fibrosis , 2016, Current Treatment Options in Infectious Diseases.

[3]  C. Supuran,et al.  N-Nitrosulfonamides: A new chemotype for carbonic anhydrase inhibition. , 2016, Bioorganic & medicinal chemistry.

[4]  D. Lowe,et al.  ‘”Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection , 2016, BMC Medicine.

[5]  G. Cook,et al.  Development of a Mycobacterium smegmatis transposon mutant array for characterising the mechanism of action of tuberculosis drugs: Findings with isoniazid and its structural analogues. , 2015, Tuberculosis.

[6]  A. Spanevello,et al.  New anti-tuberculosis drugs and regimens: 2015 update , 2015, ERJ Open Research.

[7]  K. Winthrop,et al.  Nontuberculous mycobacteria infections in immunosuppressed hosts. , 2015, Clinics in chest medicine.

[8]  C. Bombardier,et al.  Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. , 2014, Chest.

[9]  R. Bhattacharyya,et al.  Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis , 2014, The Journal of Antibiotics.

[10]  Margaret M. Johnson,et al.  Nontuberculous mycobacterial pulmonary infections. , 2014, Journal of thoracic disease.

[11]  Joachim Müller,et al.  Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2). , 2013, The Journal of antimicrobial chemotherapy.

[12]  D. Gladman,et al.  Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis. , 2013, Seminars in arthritis and rheumatism.

[13]  Z-Y Zhang,et al.  Identification and pathogenicity analysis of a novel non-tuberculous mycobacterium clinical isolate with nine-antibiotic resistance. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  J. Zawilska,et al.  Prodrugs: A challenge for the drug development , 2013, Pharmacological reports : PR.

[15]  Giovanni Sotgiu,et al.  Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.

[16]  B. Gicquel,et al.  Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.

[17]  N. Clumeck,et al.  Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  G. Palù,et al.  Functional Dissection of the PE Domain Responsible for Translocation of PE_PGRS33 across the Mycobacterial Cell Wall , 2011, PloS one.

[19]  L. D. de Carvalho,et al.  Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis. , 2011, ACS medicinal chemistry letters.

[20]  M. Chung,et al.  A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds. , 2011, Current pharmaceutical design.

[21]  A. Saxena,et al.  Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv. , 2011, Bioorganic & medicinal chemistry letters.

[22]  Joachim Müller,et al.  Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. , 2011, The Journal of antimicrobial chemotherapy.

[23]  T. Macdonald,et al.  Synthesis and Antimicrobial Evaluation of Nitazoxanide‐Based Analogues: Identification of Selective and Broad Spectrum Activity , 2011, ChemMedChem.

[24]  S. Cole,et al.  Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance , 2010, Molecular microbiology.

[25]  Christopher Bachran,et al.  Targeted Enzyme Prodrug Therapies , 2010 .

[26]  T. Macdonald,et al.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. , 2010, Bioorganic & medicinal chemistry letters.

[27]  L. D. de Carvalho,et al.  Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. , 2009, Journal of medicinal chemistry.

[28]  M. Hibert.  French/European academic compound library initiative. , 2009, Drug discovery today.

[29]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[30]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[31]  B. Wolucka,et al.  Biosynthesis of D‐arabinose in mycobacteria – a novel bacterial pathway with implications for antimycobacterial therapy , 2008, The FEBS journal.

[32]  Julian Parkhill,et al.  Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. , 2008, Genome research.

[33]  D. Bonatto,et al.  In silico identification of a new group of specific bacterial and fungal nitroreductases-like proteins. , 2007, Biochemical and biophysical research communications.

[34]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[35]  Matthew A. Croxen,et al.  Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori, Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuni , 2006, Antimicrobial Agents and Chemotherapy.

[36]  K. Bagshawe.  Antibody-directed enzyme prodrug therapy (ADEPT) for cancer , 2006, Expert review of anticancer therapy.

[37]  K. Nash,et al.  Intrinsic Macrolide Resistance of the Mycobacterium tuberculosis Complex Is Inducible , 2006, Antimicrobial Agents and Chemotherapy.

[38]  P. Appelbaum,et al.  Activities of Tizoxanide and Nitazoxanide Compared to Those of Five Other Thiazolides and Three Other Agents against Anaerobic Species , 2006, Antimicrobial Agents and Chemotherapy.

[39]  J. Aínsa,et al.  Role of mycobacterial efflux transporters in drug resistance: an unresolved question. , 2006, FEMS microbiology reviews.

[40]  P. Brennan,et al.  Decaprenylphosphoryl Arabinofuranose, the Donor of the d-Arabinofuranosyl Residues of Mycobacterial Arabinan, Is Formed via a Two-Step Epimerization of Decaprenylphosphoryl Ribose , 2005, Journal of bacteriology.

[41]  M. Pavelka,et al.  Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics , 2005 .

[42]  R. Wallace,,et al.  Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. , 2005, The Journal of antimicrobial chemotherapy.

[43]  E. Banfi,et al.  Development of a microdilution method to evaluate Mycobacterium tuberculosis drug susceptibility. , 2003, The Journal of antimicrobial chemotherapy.

[44]  K. Nash.  Intrinsic Macrolide Resistance in Mycobacterium smegmatis Is Conferred by a Novel erm Gene, erm(38) , 2003, Antimicrobial Agents and Chemotherapy.

[45]  F. Portaels,et al.  Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis , 2002, Antimicrobial Agents and Chemotherapy.

[46]  D. Berg,et al.  Enzymes Associated with Reductive Activation and Action of Nitazoxanide, Nitrofurans, and Metronidazole in Helicobacter pylori , 2002, Antimicrobial Agents and Chemotherapy.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  D. Berg,et al.  Metronidazole Activation Is Mutagenic and Causes DNA Fragmentation in Helicobacter pylori and inEscherichia coli Containing a Cloned H. pylori rdxA+ (Nitroreductase) Gene , 2000, Journal of bacteriology.

[49]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[50]  F. Deist,et al.  Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. , 1998, Science.

[51]  D. Berg,et al.  Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductase , 1998, Molecular microbiology.

[52]  S T Cole,et al.  Analysis of the genome of Mycobacterium tuberculosis H37Rv. , 1998, Novartis Foundation symposium.

[53]  B. Gicquel,et al.  A reliable amplification technique for the characterization of genomic DNA sequences flanking insertion sequences. , 1998, FEMS microbiology letters.

[54]  M. Newport,et al.  A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.

[55]  B. Gicquel,et al.  Characterization of the chromosomal aminoglycoside 2'-N-acetyltransferase gene from Mycobacterium fortuitum , 1996, Antimicrobial agents and chemotherapy.

[56]  M. D. Corbett,et al.  Bioorganic Chemistry of the Arylhydroxylamine and Nitrosoarene Functional Groups , 1995 .

[57]  H. Nikaido,et al.  The envelope of mycobacteria. , 1995, Annual review of biochemistry.

[58]  S. Eykyn,et al.  Mycobacterium chelonei keratitis: A case report and review of previously reported cases , 1994, Eye.

[59]  D I Edwards,et al.  Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. , 1993, The Journal of antimicrobial chemotherapy.

[60]  W. Jacobs,et al.  Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis , 1990, Molecular microbiology.

[61]  R. Docampo,et al.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis. , 1985, Environmental health perspectives.

[62]  Miklós Müller,et al.  Antitrichomonad Action, Mutagenicity, and Reduction of Metronidazole and Other Nitroimidazoles , 1976, Antimicrobial Agents and Chemotherapy.

[63]  M. Tsukamura.  Adansonian classification of mycobacteria. , 1966, Journal of general microbiology.

[64]  J. D. Aronson.  Spontaneous Tuberculosis in Salt Water Fish , 1926 .